Form 4: Orthofix Medical Director Awarded Deferred Stock Units as Part of Compensation

Orthofix Medical Inc. Director Shweta Maniar received an award of 18,841 deferred stock units, vesting over one year, as part of her compensation.

Summary

• Orthofix Medical Inc. Director Shweta Maniar was awarded 18,841 shares of common stock in the form of deferred stock units (DSUs) on June 18, 2025.
• These DSUs were granted at a price of $0, indicating they are part of a compensation award rather than a purchase.
• The awarded DSUs will vest in full on the first anniversary of the grant date, contingent upon Ms. Maniar's continued service to the company.
• Each deferred stock unit represents a contingent right to receive one share of Orthofix Medical Inc. common stock.
• Vested DSUs will convert into common stock within 45 days of Ms. Maniar's termination of service with the issuer.
• Following this transaction, Ms. Maniar beneficially owns a total of 54,073 shares, which includes 29,506 previously reported deferred stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event that aligns director interests with shareholders, which is generally viewed favorably, but it does not indicate any new operational or financial performance.

Positives

• The award of deferred stock units aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a routine compensation event, indicating standard corporate governance practices for director remuneration.

Future Outlook

The deferred stock units are subject to a one-year vesting period, contingent on the director's continued service, indicating a future conversion of these units into common stock.

Industry Context

The award of deferred stock units is a common practice in corporate governance for publicly traded companies, used to compensate directors and align their long-term interests with shareholder value. This type of equity compensation is standard across various industries, including the medical device sector where Orthofix operates.

Comparison to Industry Standards

• The use of deferred stock units (DSUs) for director compensation is a widely adopted practice among U.S. public companies, including peers in the medical technology and orthopedic device sectors such as Stryker Corporation (SYK), Zimmer Biomet Holdings (ZBH), and Medtronic plc (MDT).
• The vesting schedule, typically tied to continued service over a period (e.g., one year), is also standard for such awards, ensuring retention and long-term commitment from board members.

Stakeholder Impact

• Shareholders: The award aligns the director's financial interests with the long-term performance of the company's stock, potentially fostering better governance and strategic decisions.
• Employees: No direct impact mentioned, but it reinforces the company's compensation structure for key personnel.

Next Steps

• The 18,841 deferred stock units are expected to vest on the first anniversary of the grant date (June 18, 2026), subject to the director's continued service.

Key Dates

Keywords

Orthofix Medical Inc., OFIX, SEC Form 4, Insider Transaction, Deferred Stock Units, Director Compensation, Equity Award, Stock Vesting